



**VGX Pharmaceuticals Announces New Product Marketing and Sales Plan
for Asia and Other Developing Regions**

Blue Bell, PA – October 26, 2006 –

VGX Pharmaceuticals announced today the plans for eventual marketing and sales of its developmental products for Asia as well as other developing regions through VGX International.

The Company's clinical development programs include PICTOVIR™ for HIV infection and VGX-410C for chronic HCV infection, which are currently in Phase II clinical trials. In addition, several new Phase I clinical trials are prepared to be initiated in 2007 with a strong pipeline, which includes VGX-150 for Melanoma and VGX-100 for Lymphoma/Leukemia and Gastric Cancer as well as VGX-1027 for the treatment of Rheumatoid Arthritis and Type 1 Diabetes.

“We at VGX have always kept our corporate focus on improving the lives of patients through new medicines and effectively delivering our products to the people who most need them,” said J. Joseph Kim, Ph.D., President and CEO of VGX Pharmaceuticals. “As we develop our compounds through rigorous clinical testing, we are also planning the most efficient and productive avenues to bring our products to our consumers worldwide. This represents an initial step in the formation of a coordinated business plan in transforming VGX Pharmaceuticals and VGX International into global pharmaceutical companies,” said Dr. Kim.

Cautionary Factors That May Affect Future Results - Materials in this Press Release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on www.vgxp.com as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

About VGX Pharmaceuticals

VGX Pharmaceuticals is a leading biopharmaceutical company with strong product candidates for the treatment of infectious diseases including HIV and hepatitis C virus (HCV) as well as cancer and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection and VGX-410C for chronic HCV infection, which are currently in Phase II clinical trials. In addition, a Phase I clinical trial will be initiated in 2007 for the Company's lead cancer drug compound, VGX-150 for the treatment of Melanoma. Moreover, VGX Pharmaceuticals' therapeutic platform is designed to advance a strong and continual pipeline of additional drug candidates into the clinic with VGX-100 for cancer therapy and VGX-1027 and VGX-750 for inflammatory diseases currently in development. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at www.vgxp.com.

About VGX International

VGX International is a KOSPI-listed company, located in Seoul, Korea with more than 30 years in manufacturing and marketing industries. In 2005, the Company initiated a Biopharmaceutical division with collaborations with VGX Pharmaceuticals. In addition to a plan to initiate building an API manufacturing facility with the API agreement signed with VGX Pharmaceuticals in 2006, the Company is in the process of launching new drug developments for stomach cancer and type 1 diabetes among others. Furthermore, VGX International will formulate marketing strategies for such new drugs in Asia and other developing regions. More information about VGX International can be found at www.vgxi.com.

Company Contact:

Kevin W. Rassas

Senior Vice President

Tel. 267.440.4208

Fax 267.440.4242

E-mail: Rassas@vgxp.com

www.vgxp.com